Hansoo Michael Keyoung - 16 Sep 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)

Reporting relationship: Director
Issuer ticker: KAPA
Reported as of: 16 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Nov 2025, 17:27:13 UTC
Prior SEC filing: 24 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Hansoo Michael Keyoung

Key filing fact

Hansoo Michael Keyoung filed Form 4 for Kairos Pharma, LTD. (KAPA) on 26 Nov 2025.

Key facts

This page summarizes Hansoo Michael Keyoung's Form 4 filing for Kairos Pharma, LTD. (KAPA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 26 Nov 2025, 17:27.

Change

Previous filing in this sequence was filed on 24 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001824764 Primary reporting owner

Keyoung Hansoo Michael

Relationship: Director
Address: C/O KAIROS PHARMA, LTD., 2355 WESTWOOD BLVD, #139, LOS ANGELES
Signature: /s/ Hansoo Michael Keyoung
Signature date: 26 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KAPA transaction

COMMON STOCK

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 16 Sep 2025
Ownership: Direct
Footnotes: F1, F2

KAPA transaction

COMMON STOCK

Award

Transaction value: $0
Shares: +19,084
Change %: +191%
Price: $0.000000
Shares after: 29,084
Date: 08 Oct 2025
Ownership: Direct
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and grant in substantially equal installments on the anniversary date of the IPO.

Footnote F2

Consists of (i) 3,334 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting.

Footnote F3

Represents 19,084 RSUs) issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.

Footnote F4

Consists of (i) 3,334 shares of common stock and (ii) 25,750 RSUs which remain subject to vesting.